ALPHA2: Is ALLO-501A a promising alternative to autologous CAR T-cells?

During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Frederick Locke, Moffitt Cancer Center, Tampa, US. We asked, Is ALLO-501A a promising alternative to autologous CAR T-cells?

ALLO-501A is an off-the-shelf, anti-CD19 allogeneic CAR T-cell therapy which is gene edited to disrupt the TCRα gene to reduce GvHD risk, as well as the CD52 gene to allow the use of ALLO-647, an anti-CD52 mAb, for lymphodepletion without affecting grafted CAR T-cells. Locke evaluates safety and efficacy results from the phase II ALPHA2 trial, investigating ALLO-647 in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).